Sign Out
LANVIS like other cytotoxic agents is potentially teratogenic.
There have been isolated cases where men who have received combinations of cytotoxic agents including LANVIS, have fathered children with congenital abnormalities.
The use of LANVIS should be avoided whenever possible during pregnancy, particularly during the first trimester. In any individual case the potential hazard to the foetus must be balanced against the expected benefit to the mother.
As with all cytotoxic chemotherapy, adequate contraceptive precautions should be advised when either partner is receiving LANVIS.
There are no reports documenting the presence of thioguanine or its metabolites in maternal milk. It is suggested that mothers receiving LANVIS should not breast feed.
